|Videos|October 19, 2021
Patient Case #2 Continued: Novel Second-Generation Antipsychotics
A panel of experts in psychiatry consider the use of a novel second-generation antipsychotic for the management of treatment resistant depression.
Advertisement
Episodes in this series
Advertisement
Related to this article
Phase 2 data show RAP-219 eases acute bipolar mania with significant YMRS gains and encouraging tolerability, setting the stage for FDA talks and phase 3 plans.
Advertisement
Advertisement
Trending on Psychiatric Times
1
Dementia and the Tuberculosis Vaccine: Reduced Tau Burden With Administration in Mice
2
GLP-1 Receptor Agonists May Reinforce Restriction in Patients With Eating Disorders
3
ALKS 7290 for Adjunctive Treatment for MDD Enters Phase 2 Study
4
October 2026 in Review: Updates on the Psychiatric Treatment Pipeline, FDA News
5